Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK12 | Q9NYV4 | 14/20 | 0.44 |
| ▸ | CCNK | O75909 | 13/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.42 |
| ▸ | CDK7 | P50613 | 8/20 | 0.42 |
| ▸ | CCNH | P51946 | 8/20 | 0.42 |
| ▸ | MNAT1 | P51948 | 8/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.42 |
| ▸ | CDK2 | P24941 | 7/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135509 | 1.00 | CDK12 (0.44) | CDK12CCNKPAK1CDK7CCNH | |
| SCHEMBL20134870 | 0.84 | CDK12 (0.44) | CDK12CCNKPAK1CDK7CCNH | |
| SCHEMBL20134868 | 0.84 | CDK12 (0.44) | CDK12CCNKPAK1CDK7CCNH | |
| SCHEMBL20135326 | 0.83 | CCNK (0.39) | CDK12CCNKPAK1CDK7CCNH | |
| SCHEMBL20135333 | 0.83 | CCNK (0.39) | CDK12CCNKPAK1CDK7CCNH | |
| SCHEMBL20135468 | 0.82 | CYP19A1 (0.42) | CYP19A1 | |
| SCHEMBL29689169 | 0.82 | CYP19A1 (0.42) | CYP19A1 | |
| SCHEMBL20134960 | 0.82 | CYP19A1 (0.42) | CYP19A1 | |
| SCHEMBL20134962 | 0.82 | CYP19A1 (0.42) | CYP19A1 | |
| SCHEMBL20135617 | 0.81 | CCNK (0.46) | CDK12CCNKPAK1CDK7CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | CDK12 2429/4885CCNK 2686/4885PAK1 2256/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | CDK12 2332/4885CCNK 2435/4885PAK1 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.